Enhancing delivery of large neutral amino acid drugs

Details Enhancing delivery of large neutral amino acid drugs Enhancing delivery of large neutral amino acid drugs

1995-09-21

1997-12-09

Sayala, Chhaya D.

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Oxidoreductases

424 941, 4241461, 424542, 514564, A61K 3844, A61K 31195

Patent

active

056957513

ABSTRACT:
L-amino acid oxidase is utilized to reduce the plasma level of large neutral amino acids to allow the opportunity of increased large neutral amino acid drug transport across the blood brain barrier. Preferably anti L-amino acid oxidase antibody is administered intermediate to the L-amino acid oxidase and large neutral amino acid drug administrations to deplete L-amino acid oxidase activity once the L-amino acid oxidase has caused the large neutral amino acid drug transport improving level plasma reduction of large neutral amino acids thereby to reduce or eliminate degrading of large neutral amino acid drugs by L-amino acid oxidase. The large neutral amino acid drugs include levodopa, melphalan, L-DON, azaserine, acivicin, L-alanosine and 3-(phosphonomethyl)phenylalanines. For treatment of brain tumors, the drug administration is preferably preceded by the administration of a large neutral amino acid glutathione depleting agent, e.g., L-buthionine-SR-sulfoximine. L-Amino acid oxidase is also utilized to enhance the transport of large neutral amino acid glutathione depleting agent across the blood brain barrier as an adjunct to radiation therapy of brain tumors.

REFERENCES:
patent: 4772632 (1988-09-01), Vistica
patent: 4997651 (1991-03-01), Poole et al.
patent: 5075108 (1991-12-01), McKenzie et al.
Rich, J. N., et al, Cancer Chemother Pharmacol, 36, 379-384 (1995).
Wellner, D., et al, Fed. Proc. 31, p. 921, abstract 4019 (1972).
Friedman, H.S., et al, Proceedings of the American Association for Cancer Research, vol. 32, p. 318 Abstract 1886 (Mar. 1991).
The Merck Index, 11th edition, pp. 68 and 914 (1989).
Wellner, D., et al, J. Biol. Chem. 235, 2013-2108 (1960).
Barlogie, B., et al, Blood, vol. 67, No. 5 (May), 1298-1301 (1986).
Groothuis, D. R., et al, Cancer Research 52, 5590-5596 (Oct. 1992).
Momma, S, et al, Proceedings of AACR, vol. 26, p. 357, abstract #1408 (Mar. 1985).
Sarosy, G., et al, J. Clin. Oncol., vol. 6, No. 11, 1768-1782 (Nov. 1988).
Bloom, H. J. G., et al, Int. J. Radiation Oncology Biol. Phys., vol. 8, 1083-1113 (1982).
Horowitz, M. E., J. of Clin. Oncol., vol. 6, No. 2, 308-314 (Feb. 1988).
Houghton, J. A., Cancer Treatment Reports, vol. 69, No. 1, 91-96 (Jan. 1985).
Vistica, D. T., Proceedings of AACR and ASCO, vol. 18, p. 26, abstract #104, 1977.
Cornford, E. M., et al, Cancer Research 52, 138-143 (Jan. 1992).
Friedman, H. S., Cancer Research 46, 224-228 (Jan. 1986).
Leff, R. S., et al, J. Clin. Oncol., vol. 4, No. 11, 1586-1591 (Nov. 1986).
Prichard, J., et al, Br. J. Cancer, 45, 86-94 (1982).
Vistica, D. T., et al, Cancer Letters, 6, 345-350 (1979).
Moynihan, M. K., et al, Proceedings of AACR, vol. 36, p. 374, Abstract No. 2230 (Mar. 1995).
Friedman, H. S., et al, Cancer Research 46, 2827-2833 (Jun. 1986).
Friedman, H. S., et al, Cancer Research 48, 3189-4195 (Aug. 1988).
Rich, J. N., et al, Proceedings of AACR, vol. 34, p. 299, abstract No. 1778, dated Mar. 1993.
Ahluwalia, G. S., et al, Pharm. Ther., vol. 46, pp. 243-271 (1990).
Halperin, E. C., et al, Int. J. Radiation Oncology Biol. Phys., vol. 24, 103-109 (1992).
Goldenberg, G. J., et al, Cancer Research 30, 2285-2291 (Sep. 1970).
Goldenberg, G. J., et al, Cancer Research 37, 755-760 (Mar. 1977).
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, 1202-1208 (1975).
Pardridge, W. M., et al, Federation Proceedings, 45, 2073-2078 (Jun. 1986).
Li, Jia-He, et al, J. Med. Chem., 38, 1955-1965 (1995).
Lippitz, B. E., et al, Neurosurgery 26, 255-260 (1990).
Zaharko, D. et al., Cancer Research, vol. 52(3), pp. 3604-3609, Jul. 1992.
Rich, J.N. et al., Cancer Chemother. Pharmacol., vol. 36(5), pp. 379-384, 1995.

Affiliated with

Also associated with

Rating

Enhancing delivery of large neutral amino acid drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancing delivery of large neutral amino acid drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancing delivery of large neutral amino acid drugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1605405